Gurgaon Samachar

(Albany, US), September 21, 2026 – DelveInsight’s “Addison’s Disease Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of Addison’s Disease, historical and forecasted epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Curious to know what’s driving the Addison’s Disease market through 2036?

Download the report to understand the latest Addison’s Disease market trends and forecasts – Addison’s Disease Market Report – https://www.delveinsight.com/report-store/addisons-disease-market

Key Takeaways from the Addison’s Disease Market Report

• Addison’s disease, also known as primary adrenal insufficiency, is a rare condition caused by insufficient production of the steroid hormones cortisol and aldosterone by the adrenal cortex, the outer layers of the adrenal glands.

• According to the National Organization for Rare Disorders (NORD), approximately 1 in 100,000 people in the US have Addison’s disease.

• NORD also estimates that the prevalence of Addison’s disease ranges from 10 to 60 cases per million people in the general population, though its actual frequency is hard to determine as some cases may remain undiagnosed.

• Addison’s disease can develop at any age, though it most commonly appears in people between 30 and 50 years old.

• Treatment usually involves lifelong corticosteroid replacement therapy to replace the cortisol and aldosterone that the body no longer produces, typically taken in tablet form 2 or 3 times a day.

• The Addison’s Disease market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented across the seven major markets.

Gain a competitive edge in the Addison’s Disease Market by exploring our in-depth analysis @ Addison’s Disease Market

Addison’s Disease Market Overview

Addison’s disease, also known as primary adrenal insufficiency, is a rare condition caused by insufficient production of the steroid hormones cortisol and aldosterone by the adrenal cortex. It occurs when both adrenal cortices are damaged, resulting in reduced production of adrenocortical hormones such as cortisol, aldosterone, and androgens. Early signs may include fatigue or low energy, unusual drowsiness, muscle weakness, a low mood or irritability, reduced appetite with unintentional weight loss, frequent urination, increased thirst, and a strong craving for salty foods. Diagnosis is often made incidentally during a routine exam when a blood test shows low sodium or high potassium levels, and may be confirmed through specialized tests including the ACTH stimulation test, the insulin-induced hypoglycemia test, and x-ray examination.

Discover key developments and opportunities in the Addison’s Disease Market @ Addison’s Disease Market

Addison’s Disease Market Key Growth Drivers

• Rising prevalence of autoimmune disorders is contributing to a larger patient pool with primary adrenal insufficiency. Autoimmune adrenalitis remains a major cause of Addison’s disease, supporting demand for long-term hormone replacement therapies.

• Growing awareness and improved disease diagnosis among healthcare professionals and patients are encouraging earlier recognition of symptoms such as fatigue, weight loss, hypotension, and hyperpigmentation. Improved diagnostic testing for cortisol and adrenocorticotropic hormone (ACTH) levels is also supporting disease identification.

• Increasing demand for hormone replacement therapy is evident as patients require lifelong glucocorticoid replacement, with some also requiring mineralocorticoid therapy. Continued dependence on these treatments creates a stable and recurring demand for medications.

• Advancements in drug delivery technologies, including modified-release formulations, improved oral therapies, and alternative delivery systems, are addressing limitations associated with conventional hormone replacement. These innovations aim to better replicate physiological hormone patterns and improve treatment convenience.

Addison’s Disease Epidemiology

The epidemiology division of the report provides insights into the historical and current Addison’s Disease patient pool and forecasted trends for each of the seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders, and also provides the diagnosed patient pool and its trends along with the assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted Addison’s Disease epidemiology across the 7MM (US, EU5, and Japan) from 2022 to 2036.

Explore further details on the Addison’s Disease Market @ Addison’s Disease Market

Addison’s Disease Treatment

Treatment usually involves corticosteroid replacement therapy for life. Corticosteroid medicine is used to replace the hormones cortisol and aldosterone that the body no longer produces, and is usually taken in tablet form 2 or 3 times a day.

Addison’s Disease Drug Chapters

The drug chapter segment of the report encloses a detailed analysis of marketed drugs and late-stage (Phase III and Phase II) pipeline drugs for Addison’s Disease. It also helps to understand clinical trial details, pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases. The report details the emerging therapies under late- and mid-stage development for the treatment of Addison’s Disease.

Gain a competitive edge in the Addison’s Disease Market by exploring our in-depth analysis @ Addison’s Disease Market

Addison’s Disease Market Outlook

The market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Addison’s Disease market trends by analyzing the impact of current therapies, unmet needs, drivers and barriers, and demand for better technology. It provides a thorough analysis of the market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, and the views of key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Scope of the Addison’s Disease Market Report

• Study Period: 2022–2036

• Geographies Covered: US, EU5 (Germany, France, Italy, Spain, and the UK), and Japan

• Coverage: Current treatment practices/algorithm, emerging drugs, market share of individual therapies, market drivers, market barriers, and unmet medical needs

Table of Content

1. Key Insights

2. Executive Summary of Addison’s Disease

3. Competitive Intelligence Analysis for Addison’s Disease

4. Addison’s Disease: Market Overview at a Glance

5. Addison’s Disease: Disease Background and Overview

6. Patient Journey

7. Addison’s Disease Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Addison’s Disease Treatment

11. Marketed Products

12. Emerging Therapies

13. Addison’s Disease: Seven Major Market Analysis

14. Attribute Analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Addison’s Disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/addisons-disease-market